110 related articles for article (PubMed ID: 38606777)
1. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.
Babu S; Nicholson KA; Rothstein JD; Swenson A; Sampognaro PJ; Pant P; Macklin EA; Spruill S; Paganoni S; Gendron TF; Prudencio M; Petrucelli L; Nix D; Landrette S; Nkrumah E; Fandrick K; Edwards J; Young PR
Brain; 2024 Apr; ():. PubMed ID: 38606777
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
3. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
6. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
[TBL] [Abstract][Full Text] [Related]
11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
12. Development of a sensitive trial-ready poly(GP) CSF biomarker assay for
Wilson KM; Katona E; Glaria I; Carcolé M; Swift IJ; Sogorb-Esteve A; Heller C; Bouzigues A; Heslegrave AJ; Keshavan A; Knowles K; Patil S; Mohapatra S; Liu Y; Goyal J; Sanchez-Valle R; Laforce RJ; Synofzik M; Rowe JB; Finger E; Vandenberghe R; Butler CR; Gerhard A; Van Swieten JC; Seelaar H; Borroni B; Galimberti D; de Mendonça A; Masellis M; Tartaglia MC; Otto M; Graff C; Ducharme S; Schott JM; Malaspina A; Zetterberg H; Boyanapalli R; Rohrer JD; Isaacs AM;
J Neurol Neurosurg Psychiatry; 2022 Jul; 93(7):761-771. PubMed ID: 35379698
[TBL] [Abstract][Full Text] [Related]
13. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
16. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
17. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
18. MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Genovese MC; Berkowitz M; Conaghan PG; Peterfy C; Davy K; Fisheleva E; Gupta A; Inman D; Janiczek R; Layton M; Mitchell N; Patel J; Roberts A; Saurigny D; Smith JE; Williamson R; Tak PP
Lancet Rheumatol; 2020 Nov; 2(11):e666-e676. PubMed ID: 38279363
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]